IL1B and heart failure: Besides, it was shown that increased long-term incidence of HF hospitalizations were associated with high leukocyte counts [10].Moreover, subclinical inflammation predicts adverse prognosis in patients with established HF [11–13].Canakinumab (IL-1β inhibitor), as an inflammation inhibitor, has beenfound to be capable of reducing not only the incidence of hospitalization for heart failure but also heart failure-related mortality [13].